“I did the study initially just looking for a good night sleep. Doing the studies at NeuroTrials is totally for research. Once the drug (used during the study) is totally approved, it is feasible that you could ask a doctor to prescribe it,” said Debi Kimsey, a retired Atlanta resident who suffers from insomnia and found the research studies online and applied. “The reality is that the compensation for being a participant is good, and there is some satisfaction in knowing that you are working to help others find rest. The facility is top notch and the staff is awesome,” said Kimsey.
In addition to sleep disorders, NeuroTrials works with volunteers to study new medications effects on disorders like Parkinson's, Alzheimer's disease, migraines, and many more. View currently enrolling studies.
Read the full article from the Northside Neighbor.
If you are 55 or older with trouble sleeping, learn more about an insomnia study.
If you are 55 or older & a good sleeper, you may qualify for a healthy sleeper study.
If your sleep habits have changed since being diagnosed with Parkinson’s disease, you may qualify for a new research study examining a study drug for patients with Parkinson's disease experiencing excessive sleepiness. Qualified participants receive compensation for time & travel.
You may qualify if you:
Have you noticed as you age your quality of sleep declines? For many older adults, sleep problems just seem to come with the territory of aging. NeuroTrials Research is seeking to change that- we are currently enrolling for a research study for older adults with trouble sleeping.
Dr. Russell Rosenberg recently sat down with Jennifer Leslie of 11Alive to share options available for adults looking for extra shut-eye. Jennifer also spoke with current NeuroTrials Research patient Debbie Kemsey about her experience in the clinical trial.
The Hypersomnia Foundation Board of Directors and volunteers worked for more than two years with physicians and researchers to create a hypersomnia-specific registry. That of hypersomnia patients is now ready for YOU to join, and the Hypersomnia Foundation will donate $50 to research for every person who completes the Hypersomnia Foundation Patient Registry Questionnaire during the month of September!
Why are registries so important?
Registries provide critical information, particularly about rare diseases. Uncovering that information makes a rare disease easier to study, increasing the probability that a treatment can be developed.
Typically, people with rare disorders are not geographically in the same place, making it difficult for scientists and medical professionals to gather information or samples from enough patients to study a rare disorder. However, a central registry helps to overcome that geography hurdle
Why would I take the time and use my limited energy to enroll in the registry and complete the questionnaires?
Visit the new Hypersomnia Foundation Registry page to complete the form.
If you are in the Atlanta-area & are interested in participating in a currently enrolling Idiopathic Hypersomnia study, visit our study landing page.
Homer's diagnosis, and what narcolepsy looks like for non-cartoon characters.
"He's not the typical case, although the fact that he is now being identified as having narcolepsy does exemplify the fact that many people can go years and years without getting the proper diagnosis," Rosenberg said. "Who knows if they have a sleep specialist or sleep laboratory in Springfield?"
Typical patients start to show symptoms of narcolepsy when they are in their teens or 20s, although Rosenberg has seen patients as young as 2 years. Although Homer's age is difficult to pin down -- he hasn't aged much since the show debuted in December 1989 -- he's generally portrayed as being in his late 30s.
Along with excessive daytime sleepiness, people with narcolepsy usually have sleep attacks, or involuntarily episodes of slumber. These attacks can strike even when patients are doing something they enjoy, such as spending time with friends, Rosenberg said. Children may fall asleep in the middle of an activity at school, even if they are engaged in it.
About half of people with narcolepsy also have cataplexy, which causes them to lose muscle control when they feel strong emotions, such as when they're laughing, surprised or angry. Their facial muscles may droop or they may fall down. "This can be embarrassing (and) people try to blunt their emotions," Rosenberg said.
To read the full article, visit CNN.
Do you share a sleep disorder with Homer Simpson? Visit our Current Studies page to learn about research studies now enrolling for narcolepsy patients!
Primary investigator Dr. Michael Lacey & current patient Patti Eilbacher sat down with Atlanta's 11Alive to talk about the study this week.
"We are looking at a compound that works in a different way than anything that's on the market right now," Dr. Lacey said. "This medication, as opposed to just treating the symptoms, is the first real medication that's gotten this far that deals specifically with the compounds or the agents that cause the disease to progress itself, so that's very exciting for us."
For full article details, visit the 11Alive site.
For more information on the study, visit the study page.
The CEO of NeuroTrials Research, Dr. Russell Rosenberg, said the amount and quality of sleep is a top indicator or a “vital sign” of good health.
“Georgians, in particular I think, are more at risk for obesity and there’s a higher prevalence of obesity in our state, which might account for some of that daytime sleepiness,” Rosenberg said.
To read the full article and listen to the full segment on the CDC's sleep study, click here.
A drug like the one being tested, which slows the progression of the disease rather than treating symptoms like other available treatments, has not been approved by the U.S. Food and Drug Administration since 2003.The study will enroll 450 people with mild to moderate Alzheimer's. Participants must be between the ages of 55 and 85, living in a community and not a nursing home, weigh no more than 220 pounds and have a study partner with at least 10 hours of contact per week. The must also have been on one of two Alzheimer's treatments, donepezil or rivastigimine, for at least six months.
Participants will be treated for about 14 months. For more information on the study & to see if someone you know may qualify, visit our study page.
Other trial sites include Georgetown University, Mount Sinai School of Medicine, Princeton University's Medical Institute and Columbia University.
Read the full article.